Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Authors
Keywords
-
Journal
CNS SPECTRUMS
Volume 24, Issue S1, Pages 38-69
Publisher
Cambridge University Press (CUP)
Online
2019-09-04
DOI
10.1017/s109285291900124x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials
- (2019) Davy Vancampfort et al. World Psychiatry
- Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia
- (2019) Hannah E. Brown et al. JAMA Psychiatry
- Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
- (2019) Istvan Bitter et al. NEUROPSYCHOPHARMACOLOGY
- A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
- (2019) C. Michael White JOURNAL OF CLINICAL PHARMACOLOGY
- 26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia
- (2019) Steven G Potkin et al. CNS SPECTRUMS
- Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
- (2019) William F. Martin et al. AMERICAN JOURNAL OF PSYCHIATRY
- Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
- (2019) Taishiro Kishimoto et al. World Psychiatry
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- F197. Aripiprazole Lauroxil NanoCrystal® Dispersion: A Potential 1-Day Initiation Regimen for Long-Acting Aripiprazole Lauroxil
- (2018) David Walling et al. BIOLOGICAL PSYCHIATRY
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
- (2018) F. Markus Leweke et al. CNS DRUGS
- Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
- (2018) Marjie L. Hard et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases
- (2018) Michael D. Schwartz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
- (2018) Richard S. E. Keefe et al. JOURNAL OF CLINICAL PSYCHIATRY
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
- (2018) Kimberly Vanover et al. SCHIZOPHRENIA BULLETIN
- What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
- (2018) Christoph U. Correll et al. World Psychiatry
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
- (2018) Marco Solmi et al. Drug Design Development and Therapy
- Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
- (2018) Stefano Espinoza et al. Frontiers in Pharmacology
- Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial
- (2018) Xiujuan Wang et al. PSYCHIATRY RESEARCH
- A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
- (2018) Thomas A. Macek et al. SCHIZOPHRENIA RESEARCH
- Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
- (2018) Maren Carbon et al. World Psychiatry
- Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia
- (2018) Lei Sun et al. CLINICAL THERAPEUTICS
- Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
- (2017) Viktoria Moschetti et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
- (2017) Albert Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use
- (2017) Maren Carbon et al. JOURNAL OF CLINICAL PSYCHIATRY
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
- (2017) Taishiro Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
- (2017) Christoph U. Correll et al. World Psychiatry
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia
- (2017) Christoph U. Correll et al. JAMA Psychiatry
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
- (2017) Bernard L. Silverman et al. SCHIZOPHRENIA RESEARCH
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
- (2016) Ricardo P. Garay et al. EXPERT OPINION ON PHARMACOTHERAPY
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
- (2016) Christoph U. Correll et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia
- (2016) Azmi F. Nasser et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms
- (2016) Kazunori Suzuki et al. NEUROPSYCHOPHARMACOLOGY
- The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial
- (2016) J. M. Stone et al. PSYCHOLOGICAL MEDICINE
- Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
- (2016) J. P. Maia-de-Oliveira et al. PSYCHOLOGICAL MEDICINE
- Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics
- (2016) Fuminari Misawa et al. SCHIZOPHRENIA RESEARCH
- Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study
- (2016) John J. Isitt et al. SCHIZOPHRENIA RESEARCH
- Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
- (2016) Davy Vancampfort et al. World Psychiatry
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
- (2015) Jose Crippa et al. CNS & Neurological Disorders-Drug Targets
- Ambiguous findings concerning potential advantages of depot antipsychotics
- (2015) Peter M. Haddad et al. CURRENT OPINION IN PSYCHIATRY
- Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
- (2015) Richard SE Keefe et al. NEUROPSYCHOPHARMACOLOGY
- Molecular Targets of Cannabidiol in Neurological Disorders
- (2015) Clementino Ibeas Bih et al. Neurotherapeutics
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
- (2015) Christoph U. Correll et al. World Psychiatry
- Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
- (2015) Davy Vancampfort et al. World Psychiatry
- Schizophrenia
- (2015) Nature Reviews Disease Primers
- Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment
- (2014) Celine M. Laffont et al. CLINICAL PHARMACOKINETICS
- Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
- (2014) Maren Carbon et al. CNS SPECTRUMS
- Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
- (2014) Mark J. Millan et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
- (2013) Silvia Sacchi et al. CURRENT PHARMACEUTICAL DESIGN
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
- (2013) Kenji Hashimoto et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry
- (2013) John M. Kane et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone
- (2013) R. Gomeni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness
- (2013) Christoph U. Correll JOURNAL OF CLINICAL PSYCHIATRY
- Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia
- (2013) Taishiro Kishimoto et al. JOURNAL OF CLINICAL PSYCHIATRY
- Termination of Clozapine Treatment Due to Medical Reasons
- (2013) Jimmi Nielsen et al. JOURNAL OF CLINICAL PSYCHIATRY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
- (2013) John M. Kane et al. World Psychiatry
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside
- (2013) Jaime E. C. Hallak et al. JAMA Psychiatry
- A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
- (2012) Marco DiBonaventura et al. BMC Psychiatry
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Stephen S Lim et al. LANCET
- A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
- (2012) F G Revel et al. MOLECULAR PSYCHIATRY
- Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
- (2012) T. Kishimoto et al. SCHIZOPHRENIA BULLETIN
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population
- (2012) Sergey N Mosolov et al. Annals of General Psychiatry
- Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
- (2011) T Kishimoto et al. MOLECULAR PSYCHIATRY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Rethinking schizophrenia
- (2010) Thomas R. Insel NATURE
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Syntheses of novel high affinity ligands for opioid receptors
- (2009) Mark P. Wentland et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
- (2009) Christoph U. Correll JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Back to the Future
- (2008) Patrick D. McGorry et al. ARCHIVES OF GENERAL PSYCHIATRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search